Makale detayı · 2021 · article
Broadly effective metabolic and immune recovery with C5 inhibition in CHAPLE disease
Dergi
Nature Immunology
ISSN1529-2908
YÖKSİS
OpenAlex
Açık erişim · bronze
Üst %10
Yıl2021
Atıf49OpenAlex
Atıf40Semantic Scholar · 1 etkili
Yüzdelik%91,5
FWCI2,791,00 = dünya ortalaması
Scopus (SJR)Q1
WoS (JCR)Q1
Veri kaynağı ayrımı
- YÖKSİSYÖKSİS makale kaydı
- YÖKSİS dergi adıNATURE IMMUNOLOGY
- Katalog eşleşmesi (ISSN)Nature Immunology
- OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
- Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)
Özet
Özet henüz derlenmedi; DergiPark / OpenAlex kuyruğu işlenince burada görünecek.
Konular
Atıflar
OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.
49atıfOpenAlex · cited_by_count (önbellek / veritabanı)
Yerel katalogda bu makaleye atıf yapan 18 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).
- 2023 The Middle East and North Africa Diagnosis and Management Guidelines for Inborn Errors of Immunity.Atıf 63 · OpenAlex
- 2023 The Middle East and North Africa Diagnosis and Management Guidelines for Inborn Errors of ImmunityAtıf 63 · OpenAlex
- 2022 The middle east and north africa diagnosis and management guidelines for inborn errors of immunityAtıf 63 · OpenAlex
- 2022 The Middle East and North Africa Diagnosis and Management Guidelines for Inborn Errors of ImmunityAtıf 63 · OpenAlex
- 2022 The Middle East and North Africa Diagnosis and Management Guidelines for Inborn Errors of ImmunityAtıf 63 · OpenAlex
- 2022 The Middle East and North Africa Diagnosis and Management Guidelines for Inborn Errors of ImmunityAtıf 63 · OpenAlex
- 2022 The Middle East and North Africa Diagnosis and Management Guidelines for Inborn Errors of ImmunityAtıf 63 · OpenAlex
- 2024 Evaluating the Efficacy and Safety of Pozelimab in Patients with CD55 Deficiency with Hyperactivation of Complement, Angiopathic Thrombosis, and Protein-losing Enteropathy Disease: An Open-label Phase 2 and 3 StudyAtıf 34 · OpenAlex
- 2024 Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 studyAtıf 34 · OpenAlex
- 2024 Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 studyAtıf 30 · OpenAlex